 |
| Ligand ID: SWF Drugbank ID: DB00682(Warfarin) Indication:For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis. |
| DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
|---|---|---|---|---|---|---|---|---|---|---|
 Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1qz8 | POLYPROTEIN 1AB (SARSr-CoV) | 5 / 11 | PHE B 90LEU B 45LEU B 9SER A 105ALA B 107 | 1.49A | 11.21 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1wnc | E2 GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | ALA A1171LEU A1174LEU A 920SER B 919ILE B 916 | 1.42A | 11.78 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1wyy | E2 GLYCOPROTEIN (SARSr-CoV) | 6 / 11 | ALA B 940LEU B 941LEU B 944LEU B 948SER B 949ILE B1150 | 1.71A | 13.13 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1z1i | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | LEU A 205LEU A 250LEU A 253ILE A 259ALA A 260 | 1.49A | 18.70 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 11 | PHE B1230ALA B1266LEU B1268LEU B1287ILE B1281 | 1.46A | 18.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 1zv8 | E2 GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | ALA A 40LEU A 41LEU E 44ILE D 5ALA C 40 | 1.35A | 6.94 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAINREPLICASEPOLYPROTEIN 1AB,LIGHT CHAIN (SARSr-CoV) | 5 / 11 | LEU F 100LEU B 61LEU B 64ILE B 73ALA F 115 | 1.48A | 15.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 2ajf | ACE2 (Homosapiens) | 6 / 12 | LEU A 39ALA A 36PHE A 390THR A 78LEU A 100LEU A 79 | 1.56A | 21.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 2ajf | ACE2 (Homosapiens) | 6 / 12 | LEU A 39ALA A 36PHE A 390THR A 78LEU A 100LEU A 79 | 1.53A | 21.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2beq | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | ALA A 940LEU A 941LEU C 944ILE E1154ALA B 940 | 1.36A | 5.00 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2dd8 | IGG HEAVY CHAINIGG LIGHT CHAIN (Homosapiens) | 5 / 11 | ALA H 168LEU L 136SER L 138ILE L 137ALA L 175 | 1.17A | 17.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE B 148ALA B 145PHE B 96LEU B 114LEU B 173 | 1.46A | 21.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE B 148ALA B 145PHE B 96LEU B 114LEU B 173 | 1.37A | 21.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2gdt | NSP1 (EC 3.4.22.-) P65 HOMOLOGLEADER PROTEIN (SARSr) | 5 / 11 | LEU A 5LEU A 35HIS A 34LEU A 77ILE A 60 | 1.00A | 12.90 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | TRP C 423ALA E 371LEU E 374LEU C 355ILE C 345 | 1.51A | 15.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 2ghw | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE C 345PHE C 325ASN C 347THR C 320LEU C 322 | 1.40A | 16.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2hsx | LEADER PROTEIN P65 HOMOLOG NSP1 (SARSr-CoV) | 6 / 11 | PHE A 20ALA A 31LEU A 77LEU A 96LEU A 42SER A 6 | 1.70A | 12.90 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2kqv | NSP3 (SARSr-CoV) | 5 / 11 | ALA A 107LEU A 81LEU A 105SER A 69ILE A 70 | 1.50A | 15.93 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | PHE C 302LEU C 298PHE C 221LEU C 227LEU C 331 | 1.49A | 22.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | PHE C 302LEU C 298PHE C 221LEU C 227LEU C 331 | 1.41A | 22.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2rhb | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 11 | ALA F 6LEU F 2LEU C 2SER C 25ILE C 26 | 1.41A | 20.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 2wct | NSP3 (SARSr-CoV) | 5 / 11 | ALA C 415LEU C 421LEU C 437SER C 451ILE C 454 | 1.50A | 19.93 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 3d0g | ACE2SPIKE GLYCOPROTEIN (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU E 472ALA E 471LEU A 79ASN E 473LEU E 443 | 1.37A | 15.16 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 3d0g | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU A 100ALA A 99LEU A 29LEU A 392PHE A 390 | 1.42A | 21.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 3d0h | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 6 / 12 | LEU B 39ALA B 36PHE B 390THR B 78LEU B 100LEU B 79 | 1.64A | 21.53 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 3e9s | NSP3 (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.35A | 21.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 3e9s | NSP3 (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.44A | 21.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 3m3t | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | ARG A 222PHE A 219LEU A 268ALA A 267THR A 257 | 1.52A | 21.16 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 3mj5 | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.49A | 21.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 3mj5 | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE B 148PHE B 96LEU B 88LEU B 114LEU B 173 | 1.26A | 21.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU B 100ALA B 99LEU B 29LEU B 392PHE B 390 | 1.38A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 6 / 12 | LEU A 39ALA A 36PHE A 390THR A 78LEU A 100LEU A 79 | 1.72A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 4m0w | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.53A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 4m0w | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 6 / 12 | PHE A 148ALA A 146PHE A 96LEU A 88LEU A 114LEU A 173 | 1.77A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 4rna | PAPAIN-LIKE PROTEASE (Humanbetacoronavirus2cEMC/2012) | 5 / 12 | ILE A 149PHE A 148ALA A 150LEU A 169LEU A 120 | 1.41A | 21.07 | PO4 A 402 (-4.8A)NoneNoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | ARG B 278PHE B 111ALA B 274LEU B 170PHE B 183 | 1.54A | 21.39 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | LEU D 321ALA D 320PHE D 445LEU D 442LEU D 439 | 1.53A | 21.71 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 5e6j | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 11 | ALA D 132LEU D 133HIS D 176LEU D 173ALA D 154 | 1.50A | 18.88 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5e6j | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.50A | 21.78 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5e6j | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.42A | 21.78 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | ARG A 278PHE A 111ALA A 274LEU A 170PHE A 183 | 1.49A | 21.22 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5tl7 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE B 148ALA B 145PHE B 96LEU B 114LEU B 173 | 1.39A | 21.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5tl7 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE B 148ALA B 145PHE B 96LEU B 114LEU B 173 | 1.48A | 21.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5x29 | ENVELOPE SMALLMEMBRANE PROTEIN (SARSr-CoV) | 5 / 12 | PHE A 26LEU A 27PHE A 20LEU B 21PHE B 26 | 1.50A | 9.23 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5x4r | S PROTEIN (MERS-CoV) | 6 / 12 | ALA A 146PHE A 147LEU A 180LEU A 149LEU A 187PHE A 183 | 1.56A | 19.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 5x4r | S PROTEIN (MERS-CoV) | 5 / 11 | ALA A 282LEU A 265LEU A 284LEU A 169ILE A 290 | 1.49A | 18.46 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5x4r | S PROTEIN (MERS-CoV) | 5 / 12 | ALA A 146PHE A 147LEU A 149LEU A 187PHE A 183 | 1.50A | 19.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5x59 | S PROTEIN (MERS-CoV) | 5 / 12 | ALA A 146PHE A 147LEU A 149LEU A 187PHE A 183 | 1.51A | 16.42 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | LEU A 944LEU A 986THR B 991LEU A 994LEU B 994 | 1.34A | 15.83 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | ILE B 905PHE B 909ALA B 906ASN B 910PHE B 784 | 1.52A | 15.83 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5x5c | S PROTEIN (MERS-CoV) | 6 / 12 | ALA B 146PHE B 147LEU B 180LEU B 149LEU B 187PHE B 183 | 1.57A | 16.42 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 5x5c | S PROTEIN (MERS-CoV) | 5 / 11 | ALA A 282LEU A 265LEU A 284LEU A 169ILE A 290 | 1.48A | 17.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | PHE C1044LEU C 930SER C 712ILE C1000ALA C1004 | 1.50A | 17.22 | PHE C1044 ( 1.3A)LEU C 930 ( 0.6A)SER C 712 ( 0.0A)ILE C1000 ( 0.7A)ALA C1004 ( 0.0A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 5y3e | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.49A | 21.71 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 5y3q | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE A 148ALA A 145PHE A 96LEU A 114LEU A 173 | 1.41A | 21.71 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 5zvm | PAN-COV INHIBITORYPEPTIDE EK1SPIKE GLYCOPROTEIN (SARSr-CoV;syntheticconstruct) | 5 / 11 | ALA A 940LEU A 941LEU B 944ILE b 11ALA C 940 | 1.43A | 9.58 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6acd | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ARG C 99ILE C 234ALA C 233ASN C 78THR C 247 | 1.42A | 17.05 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6acd | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | ALA A 971ARG A 977LEU A 959SER A 957ALA A 954 | 1.37A | 17.30 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6acg | ACE2 (Homosapiens) | 5 / 12 | ILE D 446LEU D 240ALA D 443LEU D 585PHE D 592 | 1.52A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6ack | ACE2SPIKE GLYCOPROTEIN (Homosapiens;SARSr-CoV) | 5 / 12 | LEU C 472ALA C 471LEU D 79ASN C 473LEU C 443 | 1.21A | 17.05 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ack | ACE2 (Homosapiens) | 5 / 11 | ALA D 80LEU D 29LEU D 100LEU D 391ALA D 36 | 1.38A | 20.54 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU A 804ALA A1037PHE A 764LEU A 859LEU A 788 | 1.55A | 17.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6crx | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 11 | ALA C 926LEU C 927LEU C 920LEU C 803SER C 798 | 1.42A | 17.51 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6cs1 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | ILE C 752LEU C 745ASN C 746THR C 841LEU C 843 | 1.51A | 16.76 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6cs2 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU C 745LEU C 986ASN C 746THR C 841LEU C 843 | 1.40A | 16.76 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6cs2 | ACE2 (Homosapiens) | 5 / 11 | ALA D 443LEU D 440LEU D 444LEU D 278SER D 280 | 1.36A | 20.78 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6cs2 | ACE2 (Homosapiens) | 6 / 12 | LEU D 39ALA D 36PHE D 390THR D 78LEU D 100LEU D 79 | 1.77A | 21.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | ILE C 923PHE C 927ALA C 924ASN C 928LEU A 922 | 1.51A | 18.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 12 | PHE D 970LEU F 977LEU E1166LEU F 966PHE F 970 | 1.39A | 18.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 11 | ALA E 942LEU E 945LEU F1186SER D 940ALA D 942 | 1.25A | 11.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.75A | 21.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.74A | 21.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.76A | 21.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m0j | SPIKE RECEPTORBINDING DOMAIN (SARS-CoV-2) | 5 / 12 | ILE E 358PHE E 515ALA E 397LEU E 368LEU E 387 | 1.42A | 17.68 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m0j | ACE2 (Homosapiens) | 6 / 12 | LEU A 39ALA A 36PHE A 390THR A 78LEU A 100LEU A 79 | 1.55A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.75A | 21.24 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.78A | 21.24 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.73A | 21.24 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m17 | ACE2 (Homosapiens) | 5 / 12 | LEU D 39ALA D 36THR D 78LEU D 100LEU D 79 | 1.51A | 20.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m18 | ACE2 (Homosapiens) | 6 / 12 | LEU B 39ALA B 36PHE B 390THR B 78LEU B 100LEU B 79 | 1.53A | 20.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m18 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | ILE A 497PHE A 283LEU A 281ALA A 498PHE A 277 | 1.49A | 22.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m1d | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | LEU C 475THR C 131LEU C 201LEU C 127PHE C 473 | 1.41A | 22.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.75A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 272ALA C 234LEU C 268THR C 226LEU C 227 | 1.70A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 253ALA C 206LEU C 250LEU C 268LEU C 220 | 1.74A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 253ALA B 210PHE B 3THR B 201LEU B 268 | 1.72A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.77A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | PHE A 230ALA A 234LEU A 272LEU A 268LEU A 208 | 1.79A | 17.80 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 11 | PHE B 230ALA B 234LEU B 272LEU B 268LEU B 208 | 1.75A | 17.80 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 253ALA B 210PHE B 3THR B 201LEU B 268 | 1.70A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.77A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.78A | 20.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 685LEU A 575SER A 578ILE A 579ALA A 580 | 1.38A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | LEU D 95LEU C 56LEU C 59ILE C 68ALA D 110 | 1.51A | 15.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 634LEU A 638LEU A 576ILE A 589ALA A 688 | 1.75A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | PHE A 571ALA A 639LEU A 636LEU A 655LEU A 351 | 1.37A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862THR A 870LEU A 869PRO A 868PHE A 881 | 1.47A | 20.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 142LEU A 131LEU A 247ILE A 171 | 1.78A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 181ALA A 185LEU A 241LEU A 212LEU A 119 | 1.69A | 20.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | ALA C 65LEU C 59LEU C 71ILE D 107ALA D 110 | 1.41A | 10.04 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.61A | 18.03 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 526LEU A 527LEU A 372SER A 561ILE A 562 | 1.66A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862THR A 870LEU A 869PRO A 868PHE A 881 | 1.48A | 20.49 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 131LEU A 142LEU A 146ILE A 171 | 1.26A | 20.48 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE C 49LEU C 35THR C 9LEU C 56LEU D 98 | 1.63A | 12.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.58A | 18.03 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE A 752LEU A 745ASN A 746THR A 841LEU A 843 | 1.55A | 16.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ARG A 553LEU C 959PHE A 558LEU C 978LEU A 503 | 1.41A | 16.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6nb7 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 11 | ALA A 926LEU A 927LEU A 920LEU A 803SER A 798 | 1.35A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6nur | NSP12 (SARSr-CoV) | 5 / 11 | ALA A 130LEU A 131LEU A 142LEU A 146ILE A 171 | 1.30A | 20.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE C 358PHE C 515ALA C 397LEU C 368LEU C 387 | 1.41A | 17.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 11 | PHE B 168LEU B 153LEU B 164LEU B 160ALA B 129 | 1.75A | NoneNoneNoneSO4 B 204 (-4.7A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE A 358PHE A 515ALA A 397LEU A 368LEU A 387 | 1.36A | 17.46 | NoneNoneNoneNAG A1307 (-4.9A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE A 358PHE A 515ALA A 397LEU A 368LEU A 387 | 1.33A | 17.46 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 11 | ALA C 944LEU C 945LEU C 938LEU C 821SER C 816 | 1.48A | 17.96 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w41 | CR3022 FAB LIGHTCHAIN (Homosapiens) | 5 / 11 | ALA L 51LEU L 33LEU L 4SER L 26ILE L 2 | 1.77A | 13.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w4h | NSP16 (SARS-CoV-2) | 6 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893THR A6918LEU A6909 | 1.58A | 19.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7073PHE A6985 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6959ALA A6960THR A6891PRO A6860 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 11 | ALA A6966LEU A6852LEU A6924LEU A6887ALA A6858 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 6 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893THR A6918LEU A6909 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870PHE A6901THR A6918LEU A6909 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7010PHE A6985 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 11 | PHE B 116ALA B 124LEU B 153LEU B 140ALA B 129 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.73A | NoneNoneNoneNoneAMP A 201 ( 3.4A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 11 | ALA A6966LEU A6852LEU A6924LEU A6887ALA A6858 | 1.68A | 13.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893LEU A6909 | 1.55A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892ASN C6862LEU C7050PRO C6888LEU C7052 | 1.75A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7010PHE A6985 | 1.78A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6959ALA A6960THR A6891PRO A6860 | 1.70A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7005PHE C6985ASN C7008LEU C6924LEU C6959 | 1.80A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892ASN C6862LEU C7050PRO C6888LEU C7052 | 1.72A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 11 | ALA C6966LEU C6852LEU C6924LEU C6887ALA C6858 | 1.68A | 13.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7073PHE C6985 | 1.70A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7010PHE C6985 | 1.78A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870LEU C6893THR C6918LEU C6909 | 1.54A | 15.57 | NoneNoneNoneFMT C7113 ( 4.8A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870PHE C6901LEU C6893LEU C6909 | 1.58A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870LEU A6893THR A6918LEU A6909 | 1.51A | 15.57 | NoneNoneNoneFMT A7109 ( 4.5A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7073PHE A6985 | 1.69A | 15.57 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 118ALA B 114LEU B 152LEU B 172PHE B 147 | 1.76A | None CL B 502 ( 3.8A)NoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE C 147ALA C 145LEU C 87LEU C 113LEU C 172 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA C 116LEU C 120LEU C 172LEU C 132ALA C 176 | 1.61A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 118ALA C 114LEU C 152LEU C 172PHE C 147 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 118ALA A 114LEU A 152LEU A 172PHE A 147 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 118ALA C 114LEU C 152LEU C 172PHE C 147 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 118ALA B 114LEU B 152LEU B 172PHE B 147 | 1.74A | None CL B 502 ( 3.8A)NoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 11 | ALA A 116LEU A 120LEU A 172LEU A 132ALA A 176 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 118ALA A 114LEU A 152LEU A 172PHE A 147 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 178LEU B 125ASN B 177LEU B 132PRO B 129 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 11 | ALA A 154LEU A 153LEU A 140SER A 139ALA A 129 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wen | NSP3 (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wey | NSP3 (SARS-CoV-2) | 5 / 11 | PHE A 320ALA A 328LEU A 357LEU A 344ALA A 333 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE A 49LEU A 35THR A 9LEU A 56LEU B 98 | 1.62A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | PHE B 92LEU A 13LEU A 55SER A 54ILE B 119 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | ALA A 65LEU A 59LEU A 56ILE B 106ALA B 110 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 120ALA B 150LEU A 60PRO B 116LEU B 117 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | LEU B 95LEU A 56LEU A 59ILE A 68ALA B 110 | 1.61A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7010PHE C6985 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7073PHE A6985 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870LEU A6893THR A6918LEU A6909 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7010PHE A6985 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7073PHE C6985 | 1.68A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6959ALA A6960THR A6891PRO A6860 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870PHE C6901LEU C6893LEU C6909 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6959ALA C6960THR C6891PRO C6860 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 11 | ALA C6966LEU C6852LEU C6924LEU C6887ALA C6858 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870LEU C6893THR C6918LEU C6909 | 1.55A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 11 | ALA A6966LEU A6852LEU A6924LEU A6887ALA A6858 | 1.66A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893LEU A6909 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 11 | ALA A6966LEU A6852LEU A6924LEU A6887ALA A6858 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7073PHE A6985 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870PHE C6901LEU C6893LEU C6909 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6868ALA C6870LEU C6893THR C6918LEU C6909 | 1.54A | NoneNoneNoneFMT C7108 ( 4.9A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6959ALA A6960THR A6891PRO A6860 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870LEU A6893THR A6918LEU A6909 | 1.52A | NoneNoneNoneFMT A7108 ( 4.8A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893LEU A6909 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7005PHE C6985ASN C7008LEU C6924LEU C6959 | 1.80A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 11 | ALA C6966LEU C6852LEU C6924LEU C6887ALA C6858 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7010PHE A6985 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7010PHE C6985 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | ILE C7079LEU C6857ALA C6858LEU C7073PHE C6985 | 1.68A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | PHE B 44ALA B 55LEU B 58ILE B 86ALA B 95 | 1.79A | TRS B 402 (-4.5A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | PHE B 44ALA B 55LEU B 50LEU B 58ALA B 95 | 1.73A | TRS B 402 (-4.5A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | PHE A 44ALA A 55LEU A 58ILE A 86ALA A 95 | 1.80A | TRS A 402 (-4.4A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 11 | PHE A 44ALA A 55LEU A 50LEU A 58ALA A 95 | 1.73A | TRS A 402 (-4.4A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 12 | ALA A 161PHE A 177LEU A 73THR A 193PRO A 158 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE D 156LEU D 160LEU D 164SER D 139ALA D 129 | 1.64A | APR D 201 (-4.5A)NoneNoneNoneAPR D 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE B 116ALA B 124LEU B 153LEU B 140ALA B 129 | 1.74A | NoneNoneNoneNoneAPR B 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE C 116ALA C 124LEU C 153LEU C 140ALA C 129 | 1.74A | NoneNoneNoneNoneAPR C 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE C 156LEU C 160LEU C 164SER C 139ALA C 129 | 1.65A | APR C 201 (-4.7A)NoneNoneNoneAPR C 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE D 116ALA D 124LEU D 153LEU D 140ALA D 129 | 1.77A | NoneNoneNoneNoneAPR D 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE A 156LEU A 160LEU A 164SER A 139ALA A 129 | 1.65A | APR A 201 (-4.7A)NoneNoneNoneAPR A 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE B 156LEU B 160LEU B 164SER B 139ALA B 129 | 1.63A | APR B 201 (-4.6A)NoneNoneNoneAPR B 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.76A | NoneNoneNoneNoneAPR A 201 (-3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870LEU A6893THR A6918LEU A6909 | 1.55A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6959ALA A6960THR A6891PRO A6860 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 11 | ALA A6966LEU A6852LEU A6924LEU A6887ALA A6858 | 1.65A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 11 | TRP A6987LEU A6857LEU A6852ILE A6926ALA A6966 | 1.68A | 8NK A7103 (-3.5A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7010PHE A6985 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6868ALA A6870PHE A6901LEU A6893LEU A6909 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6857ALA A6858LEU A7073PHE A6985 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | PHE D 92LEU C 13LEU C 55SER C 54ILE D 119 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | PHE B 92LEU A 13LEU A 55SER A 54ILE B 119 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE C 49LEU C 35THR C 9LEU C 56LEU D 98 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE A 49LEU A 35THR A 9LEU A 56LEU B 98 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE B 120ALA B 150LEU A 60PRO B 116LEU B 117 | 1.62A | NoneEDO B 302 (-3.7A)NoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 11 | PHE A 230LEU A 208LEU A 205LEU A 250SER A 254 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | PHE A 147ALA A 145LEU A 87LEU A 113LEU A 172 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | ARG A 138PHE A 147LEU A 152ALA A 149THR A 102 | 1.62A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | ALA A 116LEU A 120LEU A 172LEU A 132ALA A 176 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | LEU A 118ALA A 114LEU A 152LEU A 172PHE A 147 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | ARG A 138PHE A 147LEU A 152ALA A 149THR A 102 | 1.66A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 11 | ALA A 86LEU A 152LEU A 113SER A 111ILE A 104 | 1.62A | NoneNoneNonePO4 A 502 (-2.9A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.79A | 16.70 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | ILE B 106ALA B 102ASN B 104THR A 9LEU B 91 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | PHE C 49LEU C 35THR C 9LEU C 56LEU D 98 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | PHE A 49LEU A 35THR A 9LEU A 56LEU B 98 | 1.59A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 11 | ALA B 110LEU A 71LEU A 60LEU A 56ALA A 65 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 11 | PHE D 92LEU C 13LEU C 55SER C 54ILE D 119 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 11 | ALA A 65LEU A 59LEU A 56ILE B 106ALA B 110 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE E 358PHE E 515ALA E 397LEU E 368LEU E 387 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE A 358PHE A 515ALA A 397LEU A 368LEU A 387 | 1.48A | NoneNoneNoneNoneDMS A 905 ( 4.2A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE E 358PHE E 515ALA E 397LEU E 368LEU E 387 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.80A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 219ALA A 210PHE A 3LEU A 253LEU A 271 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE E 358PHE E 515ALA E 397LEU E 368LEU E 387 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6yor | IGG L CHAIN (Homosapiens) | 5 / 11 | ALA L 57LEU L 39LEU L 4SER L 26ILE L 2 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ILE A 358PHE A 515ALA A 397LEU A 368LEU A 387 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 219ALA A 210PHE A 3LEU A 253LEU A 271 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 11 | PHE A 230LEU A 208LEU A 205LEU A 250SER A 254 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE D 116ALA D 124LEU D 153LEU D 140ALA D 129 | 1.75A | NoneNoneNoneNoneEDO D 205 (-4.5A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE B 116ALA B 124LEU B 153LEU B 140ALA B 129 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE E 116ALA E 124LEU E 153LEU E 140ALA E 129 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE C 116ALA C 124LEU C 153LEU C 140ALA C 129 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE E 116ALA E 124LEU E 153LEU E 140ALA E 129 | 1.76A | NoneNoneNoneNoneAPR E 201 (-3.5A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE C 116ALA C 124LEU C 153LEU C 140ALA C 129 | 1.79A | NoneNoneNoneNoneAPR C 201 (-3.6A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.78A | NoneNoneNoneNoneAPR A 201 ( 3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE D 116ALA D 124LEU D 153LEU D 140ALA D 129 | 1.78A | NoneNoneNoneNoneAPR D 201 (-3.4A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE B 116ALA B 124LEU B 153LEU B 140ALA B 129 | 1.79A | NoneNoneNoneNoneAPR B 201 (-3.6A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE B 116ALA B 124LEU B 153LEU B 140ALA B 129 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE A 116ALA A 124LEU A 153LEU A 140ALA A 129 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 11 | PHE C 116ALA C 124LEU C 153LEU C 140ALA C 129 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 131LEU A 142LEU A 146ILE A 171 | 1.20A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 526LEU A 527LEU A 372SER A 561ILE A 562 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.68A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 142LEU A 131LEU A 247ILE A 171 | 1.80A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 634LEU A 638LEU A 576ILE A 589ALA A 688 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 685LEU A 575SER A 578ILE A 579ALA A 580 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7btf | NSP12 (SARS-CoV-2) | 5 / 11 | PHE A 571ALA A 639LEU A 636LEU A 655LEU A 351 | 1.38A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 181ALA A 185LEU A 241LEU A 212LEU A 119 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE C 49LEU C 35THR C 9LEU C 56LEU D 98 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 206LEU A 250LEU A 268LEU A 220 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 253ALA A 210PHE A 3THR A 201LEU A 268 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 685LEU A 575SER A 578ILE A 579ALA A 580 | 1.39A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ALA A 660PHE A 348LEU A 329PRO A 328LEU B 117 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 11 | LEU D 95LEU C 13LEU C 59SER C 57ILE D 106 | 1.61A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 131LEU A 142LEU A 146ILE A 171 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 11 | PHE A 571ALA A 639LEU A 636LEU A 655LEU A 351 | 1.41A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | PHE C 49LEU C 35THR C 9LEU C 56LEU D 98 | 1.66A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 192ALA A 195LEU A 89PRO A 232PHE A 222 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 181ALA A 185LEU A 207LEU A 212LEU A 119 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862THR A 870LEU A 869PRO A 868PHE A 881 | 1.50A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | ILE D 106ALA D 102ASN D 104THR C 9LEU D 91 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 634LEU A 638LEU A 576ILE A 589ALA A 688 | 1.66A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 634LEU A 638LEU A 576ILE A 589ALA A 688 | 1.71A | NoneNoneNoneNoneF86 P 102 ( 4.1A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 130LEU A 131LEU A 142LEU A 146ILE A 171 | 1.20A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_A_SWFA502_1 (CYTOCHROME P450 2C9) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | ARG A 181ALA A 185LEU A 241LEU A 212LEU A 119 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | ALA A 685LEU A 575SER A 578ILE A 579ALA A 580 | 1.49A | A T 11 ( 4.7A)NoneNoneNone A T 13 ( 3.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117ALA A 382ASN B 118LEU A 388PHE A 396 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1OG5_B_SWFB502_1 (CYTOCHROME P450 2C9) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 862THR A 870LEU A 869PRO A 868PHE A 881 | 1.58A | U P 17 ( 4.9A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | TRP A 509LEU A 372LEU A 527ILE A 536ALA A 376 | 1.65A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 1HA2_A_SWFA3001_1 (SERUM ALBUMIN) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 11 | PHE A 571ALA A 639LEU A 636LEU A 655LEU A 351 | 1.48A | None |